Nothing Special   »   [go: up one dir, main page]

AR070413A1 - Inhibidores macrociclicos de proteasa de serina - Google Patents

Inhibidores macrociclicos de proteasa de serina

Info

Publication number
AR070413A1
AR070413A1 ARP090100353A ARP090100353A AR070413A1 AR 070413 A1 AR070413 A1 AR 070413A1 AR P090100353 A ARP090100353 A AR P090100353A AR P090100353 A ARP090100353 A AR P090100353A AR 070413 A1 AR070413 A1 AR 070413A1
Authority
AR
Argentina
Prior art keywords
heterocyclyl
alkyl
aryl
alkynyl
cycloalkyl
Prior art date
Application number
ARP090100353A
Other languages
English (en)
Original Assignee
Idenix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Pharmaceuticals Inc filed Critical Idenix Pharmaceuticals Inc
Publication of AR070413A1 publication Critical patent/AR070413A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se provee compuestos inhibidores macrocíclicos de proteasa de serina, composiciones farmacéuticas que comprenden los compuestos y su proceso de preparacion. Además se proveen métodos para su uso en el tratamiento de una infeccion por HCV en un huésped que lo necesite. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) o un unico enantiomero, una mezcla racémica, o una mezcla de sus diastereomeros; o su sal, solvato o prodroga farmacéuticamente aceptable; en donde: R5 es -OH, -NR8R9, -NHS(O)2R8, -NHS(O)2NR8R9, -NHC(O)R8, -NHC(O)NR8R9, -C(O)R9, o -C(O)NR8R9, en donde cada R8 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, heterociclilo, aIquiIo C1-6-cicloalquileno C3-7, -CH2NR8aR8b, -CH(R8c)NR8aR8b, -CHR8cCHR8dNR8aR8b, o -CH2CR8cR8dNR8aR8b, en donde: cada R8a, R8c, y R8d es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, heterociclilo, arilo C6-4-alquileno C1-6, y cada R8b es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, heterociclilo, -S(O)kR11, -S(O)kNR11R12, -C(O)R11, -C(O)OR11, -C(O)NR11R12, o -C(=NR13)NR11R12; en donde cada R11, R12, y R13 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, o R11 y R12 junto con el átomo de N al cual están unidos forman heterociclilo; o R8a y R8b junto con el átomo de N al cual están unidos forman heterociclilo; y cada R9 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, o R8 y R9 junto con el átomo de N al cual están unidos forman heterociclilo; R6 es hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, L es una ligadura, alquileno C1-6, cicloalquileno C3-7, alquenileno C2-6, alquinileno C2-6, X, o -(CR6aR6b)pX-; en donde p es un numero entero de 1, 2, o 3; R6a y R6b son cada uno independientemente hidrogeno, halo, ciano, hidroxilo, o alcoxi; y X es -O-, -C(O)-, -C(O)O-, -OC(O)O-, -C(O)NR14-, -NR14-, -NR14C(O)NR15-, -C(=NR14)NR15-, -NR14C(=NR15)NR16-, -S(O)k-, -S(O)kNR14-, -NR14S(O)kNR15-, -P(O)(OR14)-, o -OP(O)(OR14)-, donde cada R14, R15, y R16 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, y cada k es independientemente un numero entero de 1 o 2; Q1 es -O-, -N(R17)-, -C(R18R19)-, o -CR17(NR18R19)-; en donde: cada R17 y R18 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, y cada R19 es independientemente -R20, -C(O)R20, -C(O)OR20, -C(O)NR21R22, -C(=NR20)NR21R22, o -S(O)kR20; donde cada R20, R21, y R22 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, o R21 y R22 junto con el átomo de N al cual están unidos forman heterociclilo; o R18 y R19 junto con el átomo de C o N al cual están unidos forman cicloalquilo C3-7 o heterociclilo; Q2 es alquileno C3-9, alquenileno C3-9, o alquinileno C3-9, en donde cada uno contiene opcionalmente de uno a tres heteroátomos en la cadena, independientemente seleccionados de O, N, y S; y cada k es independientemente un numero entero de 1 o 2; en donde cada alquilo, alquileno, alquenilo, alquenileno, alquinilo, alquinileno, arilo, cicloalquilo, cicloalquileno, heterociclilo y heteroarilo es opcionalmente sustituido con uno o más grupos, cada uno independientemente seleccionado de ciano, halo, o nitro; alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, cada uno opcionalmente sustituido con uno o más sustituyentes Q; o -C(O)Ra, -C(O)ORa, -C(O)NRbRc, -C(NRa)NRbRc, -ORa, -OC(O)Ra, -OC(O)ORa, -OC(O)NRbRc, -OC(=NRa)NRbRc, -OS(O)Ra, -OS(O)2Ra, -OS(O)NRbRc, -OS(O)2NRbRc, -NRbRc, -NRaC(O)Rb, -NRaC(O)ORb, -NRaC(O)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(O)Rb, -NRaS(O)2Rb, -NRaS(O)NRbRc, -NRaS(O)2NRbRc, -SRa, -S(O)Ra, o -S(O)2Ra; en donde cada Ra, Rb, Rc, y Rd es independientemente hidrogeno; alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, cada uno opcionalmente sustituido con uno o más sustituyentes Q: o Rb y Rc junto con el átomo de N al cual están unidos forman heterociclilo, opcionalmente sustituido con uno o más sustituyentes Q; en donde cada Q es independientemente seleccionado del grupo que consiste en ciano, halo, o nitro; alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, o -C(O)Re, -C(O)ORe, -C(O)NRfRg, -C(NRe)NRfRg, -ORe, -OC(O)Re, -OC(O)ORe, -OC(O)NRfRg, -OC(=NRe)NRfRg, -OS(O)Re, -OS(O)2Re, -OS(O)NRfRg, -OS(O)2NRfRg, -NRfRg, -NReC(O)Rf, -NReC(O)ORf, - NReC(O)NRfRg, -NReC(=NRh)NRfRg, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NRfRg, -NReS(O)2NRfRg, -SRe, -S(O)Re, o -S(O)2Re; en donde cada Re, Rf, Rg, y Rh es independientemente hidrogeno; alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, o Rf y Rg junto con el átomo de N al cual están unidos forman heterociclilo.
ARP090100353A 2008-02-04 2009-02-03 Inhibidores macrociclicos de proteasa de serina AR070413A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2608608P 2008-02-04 2008-02-04
US8386708P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
AR070413A1 true AR070413A1 (es) 2010-04-07

Family

ID=40568607

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100353A AR070413A1 (es) 2008-02-04 2009-02-03 Inhibidores macrociclicos de proteasa de serina

Country Status (22)

Country Link
US (2) US8003659B2 (es)
EP (1) EP2250174B1 (es)
JP (1) JP5574982B2 (es)
KR (1) KR20100118991A (es)
CN (1) CN101977915B (es)
AR (1) AR070413A1 (es)
AU (1) AU2009210789B2 (es)
BR (1) BRPI0908021A2 (es)
CA (1) CA2712971A1 (es)
CO (1) CO6501153A2 (es)
CR (1) CR11618A (es)
EC (1) ECSP10010413A (es)
ES (1) ES2437147T3 (es)
HK (1) HK1144198A1 (es)
IL (1) IL207333A0 (es)
MX (1) MX2010008523A (es)
NI (1) NI201000136A (es)
NZ (1) NZ587133A (es)
RU (1) RU2490272C2 (es)
TW (1) TW200936131A (es)
WO (1) WO2009099596A2 (es)
ZA (1) ZA201005318B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. C형 간염 바이러스 복제의 신규 억제제
AR066528A1 (es) 2007-05-10 2009-08-26 Array Biopharma Inc Peptidos inhibidores de la replicacion del virus de la hepatitis c
KR20110005869A (ko) 2008-04-15 2011-01-19 인터뮨, 인크. C형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
CA2737376A1 (en) 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
EP2393822B1 (en) 2009-02-03 2014-07-16 IDENIX Pharmaceuticals, Inc. Phosphinate ruthenium complexes
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US20120142929A1 (en) * 2009-03-19 2012-06-07 Boehringer Ingelheim International Gmbh Process for preparing sulfonyl quinolines
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
ES2464367T3 (es) 2009-07-07 2014-06-02 Boehringer Ingelheim International Gmbh Composición Farmacéutica para un Inhibidor de Proteasa del Virus de la Hepatitis C
AR077688A1 (es) 2009-08-04 2011-09-14 Takeda Pharmaceutical Compuestos heterociclicos, utiles en el tratamiento de cancer
JP2013501068A (ja) * 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US20120014912A1 (en) * 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN107964006A (zh) 2012-01-11 2018-04-27 艾伯维公司 用于制备hcv蛋白酶抑制剂的方法
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
MX2015004411A (es) 2012-10-08 2016-04-06 Abbvie Inc Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc).
EA029088B1 (ru) 2013-03-15 2018-02-28 Джилид Сайэнс, Инк. Макроциклические и бициклические ингибиторы вируса гепатита c
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079912C (en) 1990-04-06 2000-07-11 Gregory Reyes Hepatitis c virus epitopes
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 c 바이러스 ns3 프로테아제의 저해제
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
US6767991B1 (en) * 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
WO1999007734A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
IL151934A0 (en) 2000-04-05 2003-04-10 Schering Corp Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
WO2001081325A2 (en) 2000-04-19 2001-11-01 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1301527A2 (en) 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
CZ2003195A3 (cs) 2000-07-21 2003-04-16 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
KR100939155B1 (ko) 2000-07-21 2010-01-28 쉐링 코포레이션 C형 간염 바이러스의 ns3-세린 프로테아제 억제제로서의신규한 펩티드
JP3889708B2 (ja) 2000-11-20 2007-03-07 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎トリペプチド阻害剤
JP4368581B2 (ja) 2000-12-12 2009-11-18 シェーリング コーポレイション C型肝炎ウイルスのns3−セリンプロテアーゼ阻害剤としてのジアリールペプチド
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6727366B2 (en) 2000-12-13 2004-04-27 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
US20040110126A1 (en) * 2001-03-08 2004-06-10 George Kukolj Hcv polymerase inhibitor assay
JP4558314B2 (ja) * 2001-07-20 2010-10-06 ベーリンガー インゲルハイム (カナダ) リミテッド ウイルスポリメラーゼインヒビター
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370400A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2004043339A2 (en) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
JP4312718B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎ウイルス阻害剤
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
WO2003099316A1 (en) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040033959A1 (en) * 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2003264038A1 (en) * 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
EP1590442A4 (en) * 2003-02-07 2007-07-18 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
CA2516018C (en) 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
CA2516016C (en) * 2003-03-05 2012-05-29 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
US7148347B2 (en) * 2003-04-10 2006-12-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
KR20060008877A (ko) 2003-04-10 2006-01-27 베링거 인겔하임 인터내셔날 게엠베하 루테늄 착물 촉매 존재하의 복분해 반응에 의한거대사이클릭 화합물의 제조방법
JP2006526011A (ja) 2003-04-11 2006-11-16 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ(特に、hcvns3−ns4aプロテアーゼ)のインヒビター
DE602004019518D1 (de) * 2003-04-16 2009-04-02 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
CA2522561C (en) * 2003-04-18 2012-07-17 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
EP1654261B1 (en) * 2003-05-21 2007-11-14 Boehringer Ingelheim International GmbH Hepatitis c inhibitor compounds
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1673385B1 (en) * 2003-09-22 2011-03-02 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
KR20120010278A (ko) * 2003-10-10 2012-02-02 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의 억제제
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
DE10348044A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US7132504B2 (en) * 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1687021B1 (en) * 2003-11-20 2013-11-06 Boehringer Ingelheim International GmbH Method of removing transition metals, especially from metathesis reaction products
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7253160B2 (en) * 2003-11-20 2007-08-07 Schering Corporation Depeptidized inhibitors of hepatitis C virus NS3 protease
US7109344B2 (en) * 2003-12-04 2006-09-19 Boehringer Ingelheim International Gmbh Ruthenium catalyst
ATE424926T1 (de) * 2003-12-08 2009-03-15 Boehringer Ingelheim Int Abtrennung von ruthenium-nebenprodukten durch behandlung mit überkritischen flüssigkeiten
DE602004026629D1 (de) 2003-12-15 2010-05-27 Japan Tobacco Inc Cyclopropanderivate und ihre pharmazeutische verwendung
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
ES2358333T3 (es) 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
EP1711514B1 (en) 2004-01-28 2008-12-03 Boehringer Ingelheim International GmbH Method of removing transition metals from reaction solutions comprising transition metal byproducts
CA2552317C (en) 2004-01-30 2013-12-10 Medivir Ab Hcv ns-3 serine protease inhibitors
JP4874227B2 (ja) 2004-02-27 2012-02-15 シェーリング コーポレイション C型肝炎ウイルスのns3セリンプロテアーゼインヒビターとしての環状p4’sを有する新規ケトアミド
KR20060127162A (ko) 2004-02-27 2006-12-11 쉐링 코포레이션 C형 간염 바이러스 ns3 세린 프로테아제의 억제제로서의화합물
CA2556917C (en) 2004-03-15 2013-07-09 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic compounds
CA2568008C (en) 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Process for preparing acyclic hcv protease inhibitors
JP4914348B2 (ja) 2004-06-28 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎インヒビターペプチド類似体
DE102004033312A1 (de) * 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
KR20070034119A (ko) * 2004-07-16 2007-03-27 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
ATE512971T1 (de) * 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
JP2008511633A (ja) 2004-08-27 2008-04-17 シェーリング コーポレイション C型肝炎ウィルスns3セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物
US7189844B2 (en) * 2004-09-17 2007-03-13 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
BRPI0517463A (pt) 2004-10-21 2008-10-07 Pfizer inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos
DE102005002336A1 (de) * 2005-01-17 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Hcvns3プロテアーゼ阻害剤
US7592336B2 (en) * 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
US7470664B2 (en) * 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
JP2009501732A (ja) 2005-07-20 2009-01-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎インヒビターペプチド類似体
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド C型肝炎ウイルス複製の新規大環状阻害剤
BRPI0614637A2 (pt) 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos do vìrus da hepatite c
WO2007017144A2 (en) * 2005-07-29 2007-02-15 Medivir Ab Macrocylic inhibitors of hepatitis c virus
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
TWI412535B (zh) 2005-07-29 2013-10-21 Tibotec Pharm Ltd C型肝炎病毒之大環抑制劑(五)
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN101277950B (zh) 2005-08-02 2013-03-27 弗特克斯药品有限公司 丝氨酸蛋白酶抑制剂
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP1934243B1 (en) 2005-09-09 2011-05-25 Boehringer Ingelheim International GmbH Ring-closing metathesis process for the preparation of macrocyclic peptides
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101401438B (zh) * 2006-03-15 2013-03-27 英国电讯有限公司 视频编码
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
KR20080104366A (ko) 2006-04-11 2008-12-02 노파르티스 아게 Hcv 억제제
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US8268776B2 (en) * 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20080187516A1 (en) 2006-06-06 2008-08-07 Ying Sun Acyclic oximyl hepatitis c protease inhibitors
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US20070281884A1 (en) 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
AR061629A1 (es) * 2006-06-26 2008-09-10 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. C형 간염 바이러스 복제의 신규 억제제
EP2049474B1 (en) * 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
BRPI0714343A2 (pt) * 2006-07-13 2013-03-19 Achillion Pharmaceuticals Inc peptÍdeos de 4-amino-4-oxobutanoil como inibidores de replicaÇço viral
EP1881002A1 (en) 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
WO2008009253A1 (de) * 2006-07-21 2008-01-24 Schaeffler Kg Verfahren zum erkennen eines laschentyps bei einer kette
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
WO2008019289A2 (en) * 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US20090035271A1 (en) * 2007-08-01 2009-02-05 Ying Sun Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US20080038225A1 (en) * 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US7662779B2 (en) * 2006-08-11 2010-02-16 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis C serine protease inhibitors
US20090035268A1 (en) * 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US8343477B2 (en) * 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107623A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080107625A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
WO2008057995A2 (en) * 2006-11-02 2008-05-15 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) * 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) * 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2150548B1 (en) 2007-04-24 2010-12-08 F. Hoffmann-La Roche AG Process for hcv protease inhibitor intermediate
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
US7910587B2 (en) 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US20080287449A1 (en) 2007-04-26 2008-11-20 Deqiang Niu Aza-tripeptide hepatitis c serine protease inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US20080292587A1 (en) 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
US20080274080A1 (en) 2007-04-26 2008-11-06 Yat Sun Or Aza-peptide macrocyclic hepatitis c serine protease inhibitors
US20080286233A1 (en) 2007-04-26 2008-11-20 Ying Sun Piperizinyl macrocyclic hepatitis c serine protease inhibitors
US20080317712A1 (en) 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
US20080274082A1 (en) 2007-04-26 2008-11-06 Yonghua Gai Oximyl hydroxyamic analogs as hepatitis c virus protease inhibitor
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009005676A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
KR20100038417A (ko) * 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TW200918524A (en) * 2007-06-29 2009-05-01 Gilead Sciences Inc Antiviral compounds
WO2009014730A1 (en) * 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8163693B2 (en) * 2007-09-24 2012-04-24 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8263549B2 (en) * 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
MX2010006209A (es) * 2007-12-05 2010-08-10 Enanta Pharm Inc Derivados de quinoxalinilo.
CA2708047A1 (en) * 2007-12-06 2009-06-11 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis c protease inhibitors

Also Published As

Publication number Publication date
BRPI0908021A2 (pt) 2015-07-21
TW200936131A (en) 2009-09-01
US8093379B2 (en) 2012-01-10
JP5574982B2 (ja) 2014-08-20
US8003659B2 (en) 2011-08-23
RU2490272C2 (ru) 2013-08-20
NI201000136A (es) 2011-03-23
US20090202480A1 (en) 2009-08-13
AU2009210789A1 (en) 2009-08-13
WO2009099596A3 (en) 2009-12-03
EP2250174A2 (en) 2010-11-17
ZA201005318B (en) 2011-10-26
CN101977915B (zh) 2014-08-13
CA2712971A1 (en) 2009-08-13
ES2437147T3 (es) 2014-01-09
IL207333A0 (en) 2010-12-30
WO2009099596A4 (en) 2010-02-04
NZ587133A (en) 2012-10-26
KR20100118991A (ko) 2010-11-08
CO6501153A2 (es) 2012-08-15
JP2011520772A (ja) 2011-07-21
RU2010136973A (ru) 2012-03-20
WO2009099596A2 (en) 2009-08-13
US20100016578A1 (en) 2010-01-21
HK1144198A1 (en) 2011-02-02
ECSP10010413A (es) 2010-11-30
CN101977915A (zh) 2011-02-16
AU2009210789B2 (en) 2014-01-30
EP2250174B1 (en) 2013-08-28
MX2010008523A (es) 2010-08-31
CR11618A (es) 2011-01-31

Similar Documents

Publication Publication Date Title
AR070413A1 (es) Inhibidores macrociclicos de proteasa de serina
AR076251A1 (es) Inhibidores de la proteasa serina macrociclica
AR077712A1 (es) Inhibidores de serina proteasa macrociclica
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR047444A1 (es) Peptidos macrociclicos activos contra el virus de la hepatitis c
CO5700736A2 (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
AR081994A1 (es) Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres
NZ612159A (en) Macrocyclic inhibitors of flaviviridae viruses
AR051984A1 (es) Compuestos heterociclicos como inhibidores del factor viia
ES2605152T3 (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico
AR074543A1 (es) Derivados de imidazo[1,2-a]piridin-2-il, agonistas de receptores 1-fosfato de esfingosina(1s1p1), composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes
PE20090994A1 (es) Derivados de azaindol 2,3-sustituidos como agentes antivirales
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
JP2016518359A5 (es)
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
AR105340A2 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden
CR8756A (es) Derivados de acido carboxilico bencimidazolona
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR061974A1 (es) Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
AR040335A1 (es) Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
PE20080070A1 (es) Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c
AR080725A1 (es) Analogos para el tratamiento o prevencion de infecciones por flavivirus y composiciones farmaceuticas que las comprenden
AR080945A1 (es) Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
AR064221A1 (es) Inhibidores no nucleosidos de transcriptasa inversa

Legal Events

Date Code Title Description
FB Suspension of granting procedure